Air Products & Chemicals, Ecolab, and McCormick generate gobs of cash, pay handsome dividends, and are likely to survive for decades to come.
Higher collection and disposal revenue drove the growth and pushed operating cash flow over the $1 billion mark.
A drug candidate was oh-so-close to a regulatory decision, but next month's meeting has been delayed indefinitely.
Investors have high hopes for the $2.7 billion gene editing pioneer, yet there are reasons for both optimism and pessimism.
The gene-editing approach might prove more useful outside the clinic.
Wall Street is not sold on the latest clinical results.
A major milestone gets closer with each passing day, but the stock seems to keep heading lower.
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
The world's largest producer of electricity from the wind and sun is surprisingly optimistic about the future of renewable energy.
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
The world's a pretty big place. Expand your portfolio's horizons with these international businesses.
Investors will be focused on a potentially trajectory-altering product launch, but it will be several quarters (at least) before we can start drawing conclusions about its impact.
The company pulled the trigger on a massive public stock offering. And why not?
The business announced a private placement to pad its balance sheet ahead of a major expansion.
The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.
Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.
The gene therapy developer announced higher-than-expected demand for its public stock offering.
The copper and gold miner reported solid second-quarter 2019 production results, but announced mounting challenges at an important growth asset.
Investors are excited about two new products for the genetic testing and liquid biopsy developer.
The company put a clinical hold from 2018 behind it and submitted its first-ever new drug application.